Compare Enveric Biosciences Inc (ENVB) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Hyatt Hotels Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Hyatt Hotels Corporation trades at $159.3 (market cap $14.81B). The key difference: Hyatt Hotels Corporation is far larger — about 2213.8× Enveric Biosciences Inc's market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Hyatt Hotels Corporation for 148 Days on average.
| ENVB | H | |
|---|---|---|
Market Cap | $6.69M | $14.81B |
Volume | 41,141 | 588,239 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $202.09 |
52-Week Low | $1.27 | $135.42 |
Typical Hold Time | 14 Days | 148 Days |
Enterprise Value | -$1.60M | $18.71B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Hyatt Hotels (H) trades at $159.43, up 0.19% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock has beaten earnings estimates for the last three quarters, though Q3 2026 results are pending. Revenue grew to $7.10 billion in 2025, but net income was negative $52 million, reflecting margin pressure. Recent news highlights brand expansion and a strategic loyalty collaboration with Delta Air Lines, signaling growth initiatives amid mixed financial performance.
The outlook for Hyatt is cautiously optimistic, supported by analyst consensus and strategic partnerships, but high valuation multiples and inconsistent profitability pose risks. Upside potential exists if operational improvements and fee growth materialize, yet investors face headwinds from debt levels and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
